Bayer shares: Analysis by Morgan Stanley analyst Thibault Boutherin on the phase III study of elinzanetant. Positive outlook and price target of 52 euros maintained.

Bayer shares: Analysis by Morgan Stanley analyst Thibault Boutherin on the phase III study of elinzanetant. Positive outlook and price target of 52 euros maintained.

According to a report by www.finanzen.net, Bayer shares were rated by Morgan Stanley analyst Thibault Boutherin. The US investment bank has left Bayer's rating at "Equal-weight" with a price target of 52 euros following positive phase III study data for the drug Elinzanetant against menopausal symptoms. The results of the study showed positive results on hot flashes as well as secondary endpoints with regard to fewer sleep disorders.

Bayer shares were temporarily up 0.88 percent at EUR 35.55 in the XETRA session. The most recent trading volume was 1,924,801 Bayer shares. Since the beginning of 2024, the share has risen by 5.8 percent. The results for Q4 2023 are scheduled to be presented on March 5, 2024.

The aforementioned positive study results and the price target of 52 euros could have a positive impact on the market for menopausal symptoms and the pharmaceutical sector. If the drug Elinzanetant is approved, Bayer could take a strong position in this area. This could also impact competition within the industry and strengthen the company's image. In addition, the positive result could also increase investor confidence, which could lead to a further increase in Bayer shares. However, it remains to be seen how the study results and future developments will impact the market and trading volumes.